Sister chromatid exchange studies for monitoring DNA damage and repair capacity after cytostatics in vitro and in lymphocytes of leukaemic patients under cytostatic therapy.
The effect of various cytostatic drugs was studied on the frequency of sister chromatid exchanges (SCEs) in vitro and in PHA-stimulated lymphocytes of leukaemic patients under cytostatic therapy. The lymphocyte system is a sensitive one for the detection of DNA damage after administration of cytostatic drugs in vitro. Mitomycin C, busulphan, vincristine, chlorambucil, cytosine arabinoside, cyclophosphamide and lycurim were tested. All except cyclophosphamide induced high frequencies of SCEs in the first mitosis after their administration. The experiments with PHA-stimulated lymphocytes in vivo from patients treated with cytostatics showed that cytosine arabinoside, in combination with thioguanine, did not induce higher frequencies of SCEs, whereas in patients who were treated with cyclophosphamide alone or in combination with other cytostatic drugs, there was a higher incidence of SCEs during treatment. About 10 days after the termination of the treatment the elevated freuqencies of SCEs returned to the initial level. After administration of some mutagens, especially alkylating agents in vivo, the lymphocyte system can be used to assess induced DNA repair by continuously monitoring for SCEs.
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002066:Busulfan / Q000494:pharmacology; D002478:Cells, Cultured; D002699:Chlorambucil / Q000494:pharmacology; D002842:Chromatids / Q000187:drug effects*; D003434:Crossing Over, Genetic; D003520:Cyclophosphamide / Q000494:pharmacology; D003561:Cytarabine / Q000494:pharmacology; D004260:DNA Repair; D004896:Erythritol / Q000031:analogs & derivatives / Q000494:pharmacology; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000378:metabolism; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D008698:Mesylates / Q000494:pharmacology; D008937:Mitomycins / Q000494:pharmacology; D014750:Vincristine / Q000494:pharmacology
D000970:Antineoplastic Agents; D008698:Mesylates; D008937:Mitomycins; D003561:Cytarabine; D002699:Chlorambucil; D014750:Vincristine; D003520:Cyclophosphamide; D002066:Busulfan; D004896:Erythritol; C000288:ritrosulfan